Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

J. Jankovic; C. Hunter; B. Z. Dolimbek; G. S. Dolimbek; C. H. Adler; A. Brashear; C. L. Comella; M. Gordon; D. E. Riley; Kapil Dev Sethi; C. Singer; M. Stacy; D. Tarsy; M. Z. Atassi

doi:10.1212/01.wnl.0000249308.66959.43

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

J. Jankovic, C. Hunter, B. Z. Dolimbek, G. S. Dolimbek, C. H. Adler, A. Brashear, C. L. Comella, M. Gordon, D. E. Riley, Kapil Dev Sethi, C. Singer, M. Stacy, D. Tarsy, M. Z. Atassi

Neurology

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Abstract

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

Original language	English (US)
Pages (from-to)	2233-2235
Number of pages	3
Journal	Neurology
Volume	67
Issue number	12
DOIs	https://doi.org/10.1212/01.wnl.0000249308.66959.43
State	Published - Dec 1 2006

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/01.wnl.0000249308.66959.43

Fingerprint Dive into the research topics of 'Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia'. Together they form a unique fingerprint.

Cite this

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. / Jankovic, J.; Hunter, C.; Dolimbek, B. Z.; Dolimbek, G. S.; Adler, C. H.; Brashear, A.; Comella, C. L.; Gordon, M.; Riley, D. E.; Sethi, Kapil Dev; Singer, C.; Stacy, M.; Tarsy, D.; Atassi, M. Z.

In: Neurology, Vol. 67, No. 12, 01.12.2006, p. 2233-2235.

Research output: Contribution to journal › Article › peer-review

@article{fa1d9cbcf646492c865546b45557fb09,

title = "Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia",

abstract = "In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.",

author = "J. Jankovic and C. Hunter and Dolimbek, {B. Z.} and Dolimbek, {G. S.} and Adler, {C. H.} and A. Brashear and Comella, {C. L.} and M. Gordon and Riley, {D. E.} and Sethi, {Kapil Dev} and C. Singer and M. Stacy and D. Tarsy and Atassi, {M. Z.}",

year = "2006",

month = dec,

day = "1",

doi = "10.1212/01.wnl.0000249308.66959.43",

language = "English (US)",

volume = "67",

pages = "2233--2235",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "12",

}

TY - JOUR

T1 - Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

AU - Jankovic, J.

AU - Hunter, C.

AU - Dolimbek, B. Z.

AU - Dolimbek, G. S.

AU - Adler, C. H.

AU - Brashear, A.

AU - Comella, C. L.

AU - Gordon, M.

AU - Riley, D. E.

AU - Sethi, Kapil Dev

AU - Singer, C.

AU - Stacy, M.

AU - Tarsy, D.

AU - Atassi, M. Z.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

AB - In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

UR - http://www.scopus.com/inward/record.url?scp=33845939760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845939760&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000249308.66959.43

DO - 10.1212/01.wnl.0000249308.66959.43

M3 - Article

C2 - 17190952

AN - SCOPUS:33845939760

VL - 67

SP - 2233

EP - 2235

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -